tirzepatide novo nordisk Nordisk's CagriSema Shows Strong Weight-Loss Results But Trails Eli Lilly's in Latest Clinical Data Novo weight-loss drug may preserve

How weight affects depression Obesity is associated with chronic low-grade inflammation

Living with psoriasis means managing a skin barrie

Retatrutide has produced notable average weight loss in phase 2 research, yet it still needs larger studies, longer follow-up, and regulatory review before any standard dosing approach can be defined for routine care

Rather than recommending one treatment for everyone, our clinicians assess each patient individually, considering medical history, lifestyle, previous weight loss attempts and long-term health goals

This included significant reductions in the incidence of CV death, nonfatal myocardial infarction and nonfatal stroke (Lincoff et al, 2023)